Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (971-980 of 1,060) with videos related to

Pageof 106
Sort By:
European Heart Journal|March 10, 2022
The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemicMichael R Zile, Akshay S Desai, Maria Rosa Costanzo, et al.
Journal of the American College of Cardiology|September 25, 2024
Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HFShingo Matsumoto, Li Shen, Alasdair D Henderson, et al.
European Journal of Heart Failure|June 27, 2024
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HFMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
European Journal of Heart Failure|April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HFIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
Circulation|December 20, 2018
Heart Failure With Preserved Ejection Fraction in the YoungJasper Tromp, Michael R MacDonald, Wan Ting Tay, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
European Journal of Heart Failure|December 19, 2019
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fractionKieran F Docherty, Li Shen, Davide Castagno, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
Pageof 106

Showing results (971-980 of 1,060) with videos related to

Sort By:
Pageof 106
European Heart Journal|March 10, 2022
The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemicMichael R Zile, Akshay S Desai, Maria Rosa Costanzo, et al.
Journal of the American College of Cardiology|September 25, 2024
Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HFShingo Matsumoto, Li Shen, Alasdair D Henderson, et al.
European Journal of Heart Failure|June 27, 2024
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HFMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
European Journal of Heart Failure|April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HFIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
Circulation|December 20, 2018
Heart Failure With Preserved Ejection Fraction in the YoungJasper Tromp, Michael R MacDonald, Wan Ting Tay, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
European Journal of Heart Failure|December 19, 2019
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fractionKieran F Docherty, Li Shen, Davide Castagno, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
Pageof 106